Alector ALEC 深 沪
已收盘 08-07 16:00:00 美东时间
1.78
-0.050
-2.73%
华盛通- 最 高2.035
- 今 开1.84
- 成交量 121.08万股
- 最 低 1.46
- 昨 收 1.83
- 总市值 14.65万
- 52周最高 3.3999
- 市盈率 静 --
- 换手率 1470.70%
- 52周最低 1.09
- 委 比 -92.92%
- 总股本 8.23万
- 历史最高 43.32
- 量 比 0.82
- 振 幅 31.42%
- 历史最低 0.87
- 每 手 1
- 风险率 0.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多GSK's Jemperli May Help Some Rectal Cancer Patients Avoid Surgery
GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating the need for surgery or chemo.
07-13 20:16
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership
GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.
07-11 01:00
Cantor Fitzgerald Upgrades Alector to Overweight
Cantor Fitzgerald analyst Pete Stavropoulos upgrades Alector (NASDAQ:ALEC) from Neutral to Overweight.
04-15 20:08
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Wall Street analysts upgraded CRWD, ALEC, RIVN, SEDG, and DNTH. See what other analysts say about these stocks. Consider buying CRWD.
03-10 20:32
葛兰素史克(GSK)与Alector(ALEC)合作药物latozinemab未能延缓痴呆症进展
金吾财讯 | 葛兰素史克(GSK)声明其与美国生物科技公司Alector(ALEC)合作的试验性药物latozinemab未能延缓痴呆症进展，宣告又一款潜在痴呆症治疗药物研发失败。这款药物由Alector公司研发，针对的是一种名为“额颞叶痴呆”的痴呆症类型。 葛兰素史克表示将终止该临床试验并分析结果。Alector周二表示，其试验性药物在一项晚期临床试验中未能减缓一种罕见痴呆症的进展，促使该公司终止了这项研究，并裁减了近一半的员工。
2025-10-22 21:51
Alector Provides Executive Leadership Update
Alector announces Marc Grasso's departure as CFO, replaced by Neil Berkley as interim CFO. The company is advancing late-stage neurodegenerative disease therapies, with clinical trials on track, and utilizing its proprietary ABC blood-brain barrier platform for drug delivery.
2025-06-13 20:05
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Alector management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2024, at 8:40 am ET. The event will be available via live webcast and replay on Alector’s investor website.
2025-06-03 12:00
Alector Presents Baseline Data For INFRONT-3 Phase 3 Trial Of Latozinemab At ISFTD 2024, Targeting Frontotemporal Dementia With Progranulin Gene Mutation (FTD-GRN)
In July 2021, Alector Entered Into A Collaboration With GSK For Global Development And Commercialization Of Progranulin-Elevating Monoclonal Antibodies, Receiving $700M Upfront And Eligible For Up To $1.5B In Milestone
2024-09-19 20:10
Cantor Fitzgerald Reiterates Overweight on Alector
Cantor Fitzgerald analyst Josh Schimmer reiterates Alector (NASDAQ:ALEC) with a Overweight.
2024-09-10 00:51
